Complications associated with intestinal infusion therapies in patients with Parkinson’s disease: a single-center retrospective study and 15-year experience

Complications associated with intestinal infusion therapies in patients with Parkinson’s disease: a single-center retrospective study and 15-year experience

IntroductionParkinson’s disease (PD) is a progressive neurodegenerative disorder, in advanced stages characterized by motor and non-motor fluctuations, significantly impacting patients’ quality of life (QoL). Advanced therapies, such as levodopa/carbidopa intestinal gel or carbidopa/levodopa enteral...

Full description

Saved in:

Bibliographic Details
Main Authors:	Igor Straka, Zuzana Andre, Zuzana Kosutzka, Karin Gmitterova, Milos Stevove, Zuzana Durkovicova, Radovan Juricek, Peter Valkovic, Michal Minar
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Neurology
Subjects:	advanced Parkinson’s disease adverse events gastrojejunostomy levodopa/carbidopa intestinal gel (LCIG) levodopa/entacapone/carbidopa intestinal gel (LECIG)
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2025.1547557/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Target-Controlled Sedation with Propofol Infusion for PEG-J Placement in Advanced Parkinson’s Disease: A Prospective Observational Study on Safety and Feasibility
by: Janos Szederjesi, et al.
Published: (2025-03-01)

A case of Frégoli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson’s disease undergoing STN-DBS
by: Shunsuke Ogata, et al.
Published: (2025-01-01)

Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
by: Julia Węgrzynek-Gallina, et al.
Published: (2024-12-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Symptom improvement in a South Asian patient with Parkinson’s disease treated with immediate- and extended-release carbidopa–levodopa: a case report
by: Gail Reiner, et al.
Published: (2025-07-01)

Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals
by: Yi Rang Han, et al.
Published: (2025-01-01)

Buried bumper syndrome in percutaneous endoscopic gastrostomy with a jejunal extension tube in patients undergoing levodopa–carbidopa intestinal gel treatment
by: Masatoshi Nakagawa, et al.
Published: (2023-12-01)

Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC
by: Deepa D. Nakmode, et al.
Published: (2025-02-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics
by: Akane Hayashi, et al.
Published: (2025-07-01)

Parkinson&rsquo;s disease managing reversible neurodegeneration
by: Hinz M, et al.
Published: (2016-04-01)

Pain in Parkinson's disease Dor na doença de Parkinson
by: Grace Helena Letro, et al.
Published: (2009-09-01)

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

How I treat Parkinson's disease
by: Egberto Reis Barbosa, et al.
Published: (2022-08-01)

Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01)

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease
by: Xiaoqin He, et al.
Published: (2025-01-01)

Bereitschaftspotential preceding eyelid blinks in Parkinson’s disease
by: Isabella Araújo Mota, et al.

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003-01-01)

Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation Escala para qualidade de vida na doença de Parkinson - PDQ 39 (versão do Português falado no Brasil) como instrumento para avaliação de pacientes com e sem flutuação motora decorrente da levodopa
by: Renata Guzzo Souza, et al.
Published: (2007-09-01)

Tratamento da doença de Parkinson
by: Francisco Cardoso
Published: (1995-03-01)

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Novos agonistas dopaminérgicos
by: MATTOS JAMES PITÁGORAS DE, et al.
Published: (1999-01-01)

Identification of electromyographic patterns of bradykinesia in patients with Parkinson's disease
by: Nikita Kozulin, et al.
Published: (2024-10-01)

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
by: Bruno Lopes SANTOS-LOBATO, et al.
Published: (2020-04-01)

Specificity and sensibility of 9-Itens Wearing-off Questionnaire in Brazilian Parkinson disease patient sample
by: Jasper Guimarães Santos, et al.
Published: (2014-11-01)

Gastrojejunocolic Fistula: A Late Complication After Gastrojejunostomy
by: Seung Ho Sin, et al.
Published: (2024-12-01)

Working memory in Parkinson's disease patients: clinical features and response to levodopa Memória de trabalho em pacientes com doença de Parkinson: características clínicas e resposta a levodopa
by: Rogério Beato, et al.
Published: (2008-06-01)

Prosody and levodopa in Parkinsons disease
by: Luciana Lemos de Azevedo, et al.
Published: (2013-11-01)

Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction
by: Luciana Ulhôa Guedes, et al.
Published: (2012-11-01)

Dementia with Lewy bodies
by: O. S. Levin, et al.
Published: (2018-11-01)

Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s
by: Bruno Lopes dos Santos-Lobato, et al.
Published: (2016-08-01)

Efficacy and motor complications of original and generic levodopa in Parkinson&#39;s disease treatment
by: Kasemsap N, et al.
Published: (2016-05-01)

A comprehensive review of deep brain stimulation for Parkinson's disease: The history, current state of the art and future possibilities
by: Avery Foote, et al.
Published: (2025-06-01)

Translational profiling reveals novel gene expression changes in the direct and indirect pathways in a mouse model of levodopa induced dyskinesia
by: Sabika Jafri, et al.
Published: (2025-03-01)

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
by: Robert A. Hauser, et al.
Published: (2025-01-01)

Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson’s disease: a case report
by: Gabriela Rozo-Paz, et al.
Published: (2025-03-01)

Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
by: Alma Medrano-Hernández, et al.
Published: (2025-07-01)

Quantitative analysis of gait parameters in Parkinson’s disease and the clinical significance
by: Wenchao Yin, et al.
Published: (2025-08-01)

Apomorfina: uma alternativa no controle das flutuações motoras na doença de Parkinson
by: Henrique B. Ferraz, et al.
Published: (1995-06-01)